
Franz Schubiger
Partner
Attorney at law, LL.M.
Co-Head Life Sciences
Feldeggstrasse 4
8008 Zurich
Suisse
T +41 44 217 92 49
franz.schubiger@pestalozzilaw.com
Franz Schubiger co-heads Pestalozzi's Life Sciences Group and is a member of the Corporate / M&A Group in Zurich. His practice focuses on corporate law, M&A, corporate finance, private equity and venture capital, complex restructurings as well as general contract and commercial law. He regularly advises in the fields of life sciences, including pharma, consumer healthcare and medtech, as well as in the consumer goods and retailing industries and on ICT, e-commerce and online business.
Carrière
- Partner at Pestalozzi
- Cornell University: LL.M., Fulbright Scholar
- Associate at Pestalozzi
- Bar admission: Switzerland
- Associate at a Swiss law firm
- University of Zurich: lic.iur.
- Law clerk at District Courts Gaster/See
Langues
German, English, French, Italian
Compétences & Industries
Blockchain & Crypto AssetsMarchés de capitaux
Corporate / M&A
Services Financiers
Governance
Life Sciences (sciences de la vie)
Private Equity & Venture Capital
Restructuring & Insolvency
Adhésion
- ZAV/SAV
- Union Internationale des Avocats (UIA)
- Swiss-American Chamber of Commerce
- Swiss Private Equity & Corporate Finance Association (SECA)
Deals and Cases
Pestalozzi advises Martec Handels AG on the acquisition of Renuwell business
Pestalozzi advises Martec Handels AG on the acquisition of Renuwell business
Pestalozzi advises SSP in acquisition of PRET franchise business and expansion rights in German-speaking Switzerland
Pestalozzi advises SSP in acquisition of PRET franchise business and expansion rights in German-speaking Switzerland
Pestalozzi advises The European Investment Bank on a EUR 25 million venture debt transaction with GeNeuro
Pestalozzi advises The European Investment Bank on a EUR 25 million venture debt transaction with GeNeuro
Publications

Inhouse Counsels in M&A Transactions: The Selection of the Legal Advisors – A Friendly Debate
Swiss M&A - Venture Capital Investments 2023
